JP2009526072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009526072A5 JP2009526072A5 JP2008554398A JP2008554398A JP2009526072A5 JP 2009526072 A5 JP2009526072 A5 JP 2009526072A5 JP 2008554398 A JP2008554398 A JP 2008554398A JP 2008554398 A JP2008554398 A JP 2008554398A JP 2009526072 A5 JP2009526072 A5 JP 2009526072A5
- Authority
- JP
- Japan
- Prior art keywords
- indazol
- amide
- carboxylic acid
- benzimidazol
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1H-indazol-5-yl Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 102000003989 Aurora kinases Human genes 0.000 claims 3
- 108090000433 Aurora kinases Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- AISDZXDUJKGHKF-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-piperazin-1-yl-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4NN=CC4=CC=3)=C(N3CCNCC3)C=C2N1 AISDZXDUJKGHKF-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- MMWGJBJWRXZBOZ-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-6-(diethylamino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(Nc3ccc(Cl)cc3Cl)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 MMWGJBJWRXZBOZ-UHFFFAOYSA-N 0.000 claims 1
- KEFTXIIEXNSQFP-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-N-(1H-indazol-6-yl)-6-morpholin-4-yl-3H-benzimidazole-5-carboxamide Chemical compound Clc1ccc(Nc2nc3cc(C(=O)Nc4ccc5cn[nH]c5c4)c(cc3[nH]2)N2CCOCC2)c(Cl)c1 KEFTXIIEXNSQFP-UHFFFAOYSA-N 0.000 claims 1
- RSNFEDFAAUNKNC-UHFFFAOYSA-N 2-(3,5-difluoroanilino)-N-(1H-indazol-6-yl)-6-morpholin-4-yl-3H-benzimidazole-5-carboxamide Chemical compound Fc1cc(F)cc(Nc2nc3cc(C(=O)Nc4ccc5cn[nH]c5c4)c(cc3[nH]2)N2CCOCC2)c1 RSNFEDFAAUNKNC-UHFFFAOYSA-N 0.000 claims 1
- VEWNTHCXMCUYJH-UHFFFAOYSA-N 2-[(1-butylimidazol-2-yl)amino]-N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCCCn1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 VEWNTHCXMCUYJH-UHFFFAOYSA-N 0.000 claims 1
- WBARYMQGZWFQNY-UHFFFAOYSA-N 2-[(1-cyclobutylimidazol-2-yl)amino]-N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3H-benzimidazole-5-carboxamide Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3nccn3C3CCC3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 WBARYMQGZWFQNY-UHFFFAOYSA-N 0.000 claims 1
- YHQVKJDVDWVMAG-UHFFFAOYSA-N 2-[(1-cyclohexylimidazol-2-yl)amino]-N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3H-benzimidazole-5-carboxamide Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3nccn3C3CCCCC3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 YHQVKJDVDWVMAG-UHFFFAOYSA-N 0.000 claims 1
- BANFFPBKLPICNV-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-6-(4-ethylpiperazin-1-yl)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN1CCN(CC1)c1cc2[nH]c(Nc3nccn3C3CCCC3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 BANFFPBKLPICNV-UHFFFAOYSA-N 0.000 claims 1
- YQETTXJSGLCTML-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3H-benzimidazole-5-carboxamide Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3nccn3C3CCCC3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 YQETTXJSGLCTML-UHFFFAOYSA-N 0.000 claims 1
- YIMWWXUOFKGRBI-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-N-(1H-indazol-6-yl)-6-morpholin-4-yl-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1cc2nc(Nc3nccn3C3CCCC3)[nH]c2cc1N1CCOCC1 YIMWWXUOFKGRBI-UHFFFAOYSA-N 0.000 claims 1
- XNBMZVUUWHZORT-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-n-(1h-indazol-5-yl)-6-(4-methylpiperazin-1-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3C=NNC3=CC=2)=CC2=C1N=C(NC=1N(C=CN=1)C1CCCC1)N2 XNBMZVUUWHZORT-UHFFFAOYSA-N 0.000 claims 1
- MHMXIVBSMSQWOH-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-n-(1h-indazol-6-yl)-6-(4-propan-2-ylpiperazin-1-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C(C)C)CCN1C(C(=C1)C(=O)NC=2C=C3NN=CC3=CC=2)=CC2=C1N=C(NC=1N(C=CN=1)C1CCCC1)N2 MHMXIVBSMSQWOH-UHFFFAOYSA-N 0.000 claims 1
- FWXDOFFJAJEPOE-UHFFFAOYSA-N 2-[(1-cyclopentylimidazol-2-yl)amino]-n-(1h-indazol-6-yl)-6-piperazin-1-yl-3h-benzimidazole-5-carboxamide Chemical compound C=1C=C2C=NNC2=CC=1NC(=O)C(C(=CC=1N2)N3CCNCC3)=CC=1N=C2NC1=NC=CN1C1CCCC1 FWXDOFFJAJEPOE-UHFFFAOYSA-N 0.000 claims 1
- BFFQMYCYFLMCTR-UHFFFAOYSA-N 2-[(1-ethylimidazol-2-yl)amino]-N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCn1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 BFFQMYCYFLMCTR-UHFFFAOYSA-N 0.000 claims 1
- YEJWSBSLTSIZIY-UHFFFAOYSA-N 2-[(3-chloropyridin-2-yl)amino]-6-(diethylamino)-n-(1h-indazol-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=NC=CC=C1Cl YEJWSBSLTSIZIY-UHFFFAOYSA-N 0.000 claims 1
- GASNFYRDSZSJDU-UHFFFAOYSA-N 2-[2-chloro-5-(trifluoromethyl)anilino]-6-(diethylamino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(Nc3cc(ccc3Cl)C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 GASNFYRDSZSJDU-UHFFFAOYSA-N 0.000 claims 1
- OGQBIIGEBPWICU-UHFFFAOYSA-N 6-(diethylamino)-2-(2,5-difluoroanilino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(Nc3cc(F)ccc3F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 OGQBIIGEBPWICU-UHFFFAOYSA-N 0.000 claims 1
- MHVOYYLQTMGVEX-UHFFFAOYSA-N 6-(diethylamino)-2-(3,5-difluoroanilino)-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(Nc3cc(F)cc(F)c3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 MHVOYYLQTMGVEX-UHFFFAOYSA-N 0.000 claims 1
- KFYMPXUJZIUONK-UHFFFAOYSA-N 6-(diethylamino)-2-[(3-ethyl-6-methylpyridin-2-yl)amino]-N-(1H-indazol-6-yl)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2nc(Nc3nc(C)ccc3CC)[nH]c2cc1C(=O)Nc1ccc2cn[nH]c2c1 KFYMPXUJZIUONK-UHFFFAOYSA-N 0.000 claims 1
- IMNQPXYVRRLLSN-UHFFFAOYSA-N 6-(diethylamino)-N-(1H-indazol-6-yl)-2-(2-propan-2-ylanilino)-3H-benzimidazole-5-carboxamide Chemical compound CCN(CC)c1cc2[nH]c(Nc3ccccc3C(C)C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 IMNQPXYVRRLLSN-UHFFFAOYSA-N 0.000 claims 1
- ACQKCFILAOYJAH-UHFFFAOYSA-N 6-(diethylamino)-N-(1H-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=CC=CC=C1C(F)(F)F ACQKCFILAOYJAH-UHFFFAOYSA-N 0.000 claims 1
- VZVZWGALLRTOJR-UHFFFAOYSA-N 6-(diethylamino)-n-(1h-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC)CC)=CC=2NC=1NC1=NC=CC=C1C VZVZWGALLRTOJR-UHFFFAOYSA-N 0.000 claims 1
- WFKBDVICDXSCBN-UHFFFAOYSA-N 6-(dimethylamino)-n-(1h-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(C)C)=CC=2NC=1NC1=NC=CC=C1C WFKBDVICDXSCBN-UHFFFAOYSA-N 0.000 claims 1
- JJSYIPLPEMLERA-UHFFFAOYSA-N 6-(dimethylamino)-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(C)C)=CC=2NC=1NC1=CC=CC=C1C(F)(F)F JJSYIPLPEMLERA-UHFFFAOYSA-N 0.000 claims 1
- CWMLARGLZYFTJP-UHFFFAOYSA-N 6-(dipropylamino)-N-(1H-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CCCN(CCC)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 CWMLARGLZYFTJP-UHFFFAOYSA-N 0.000 claims 1
- AZYKAQIJICDKJX-UHFFFAOYSA-N 6-[bis(2-methylpropyl)amino]-n-(1h-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound N1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(N(CC(C)C)CC(C)C)=CC=2N=C1NC1=CC=CC=C1C(F)(F)F AZYKAQIJICDKJX-UHFFFAOYSA-N 0.000 claims 1
- YIGDOBRALYFCJQ-UHFFFAOYSA-N 6-[ethyl(methyl)amino]-N-(1H-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound CCN(C)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 YIGDOBRALYFCJQ-UHFFFAOYSA-N 0.000 claims 1
- UPUZFYDYADSBFR-UHFFFAOYSA-N 6-[ethyl(propyl)amino]-N-(1H-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CCCN(CC)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 UPUZFYDYADSBFR-UHFFFAOYSA-N 0.000 claims 1
- HKKPGPCUDCXJNH-UHFFFAOYSA-N 6-[ethyl(propyl)amino]-N-(1H-indazol-6-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound CCCN(CC)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 HKKPGPCUDCXJNH-UHFFFAOYSA-N 0.000 claims 1
- 108090000461 Aurora Kinase A Proteins 0.000 claims 1
- 102100032311 Aurora kinase A Human genes 0.000 claims 1
- 102100032306 Aurora kinase B Human genes 0.000 claims 1
- 108090000749 Aurora kinase B Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- VSLORNBGAYLGEF-UHFFFAOYSA-N CC1CN(CC(C)O1)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CC1CN(CC(C)O1)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 VSLORNBGAYLGEF-UHFFFAOYSA-N 0.000 claims 1
- IYHUJCAONMPBNA-UHFFFAOYSA-N CCCN(CCC)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CCCN(CCC)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 IYHUJCAONMPBNA-UHFFFAOYSA-N 0.000 claims 1
- OWTJCECDYIEATM-UHFFFAOYSA-N CN1CCN(CC1)c1cc2[nH]c(Nc3cc(F)cc(F)c3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3cc(F)cc(F)c3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 OWTJCECDYIEATM-UHFFFAOYSA-N 0.000 claims 1
- FVVCFLZKMPPLDQ-UHFFFAOYSA-N CN1CCN(CC1)c1cc2[nH]c(Nc3ccc(Cl)cc3Cl)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3ccc(Cl)cc3Cl)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 FVVCFLZKMPPLDQ-UHFFFAOYSA-N 0.000 claims 1
- VRUMRPCYMJXMED-UHFFFAOYSA-N CN1CCN(CC1)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 VRUMRPCYMJXMED-UHFFFAOYSA-N 0.000 claims 1
- DRJKSGDFAAPDEI-UHFFFAOYSA-N CN1CCN(CC1)c1cc2[nH]c(Nc3nccn3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3nccn3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 DRJKSGDFAAPDEI-UHFFFAOYSA-N 0.000 claims 1
- ZJGUPCSKJFJOCP-UHFFFAOYSA-N COCCn1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 Chemical compound COCCn1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 ZJGUPCSKJFJOCP-UHFFFAOYSA-N 0.000 claims 1
- LUURBAICLUVVGT-UHFFFAOYSA-N Cc1cccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCOCC1 Chemical compound Cc1cccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCOCC1 LUURBAICLUVVGT-UHFFFAOYSA-N 0.000 claims 1
- MATJDJSLCYHHNM-UHFFFAOYSA-N FC(F)(F)c1ccccc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCCCC1 Chemical compound FC(F)(F)c1ccccc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCCCC1 MATJDJSLCYHHNM-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- KCVDJGFWSFUZGV-UHFFFAOYSA-N N-(1H-indazol-6-yl)-2-[(3-methylpyridin-2-yl)amino]-6-(4-propan-2-ylpiperazin-1-yl)-3H-benzimidazole-5-carboxamide Chemical compound CC(C)N1CCN(CC1)c1cc2[nH]c(Nc3ncccc3C)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 KCVDJGFWSFUZGV-UHFFFAOYSA-N 0.000 claims 1
- CEJIKJXISWFZPL-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-(1,3-thiazol-2-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound CN1CCN(CC1)c1cc2[nH]c(Nc3nccs3)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 CEJIKJXISWFZPL-UHFFFAOYSA-N 0.000 claims 1
- WHFYBXJIWPFYDR-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-[(1-pentan-3-ylimidazol-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CCC(CC)n1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 WHFYBXJIWPFYDR-UHFFFAOYSA-N 0.000 claims 1
- CJRZGNRFLQUGNM-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-[(1-propan-2-ylimidazol-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CC(C)n1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 CJRZGNRFLQUGNM-UHFFFAOYSA-N 0.000 claims 1
- OWXBQGSFKUUCAG-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-methylpiperazin-1-yl)-2-[[1-(2-methylpropyl)imidazol-2-yl]amino]-3H-benzimidazole-5-carboxamide Chemical compound CC(C)Cn1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCN(C)CC1 OWXBQGSFKUUCAG-UHFFFAOYSA-N 0.000 claims 1
- BGZNNNSDCWMGML-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-(4-propan-2-ylpiperazin-1-yl)-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound CC(C)N1CCN(CC1)c1cc2[nH]c(Nc3ccccc3C(F)(F)F)nc2cc1C(=O)Nc1ccc2cn[nH]c2c1 BGZNNNSDCWMGML-UHFFFAOYSA-N 0.000 claims 1
- YDTUTAOENNWFDW-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-morpholin-4-yl-2-(1,3-thiazol-2-ylamino)-3H-benzimidazole-5-carboxamide Chemical compound O=C(Nc1ccc2cn[nH]c2c1)c1cc2nc(Nc3nccs3)[nH]c2cc1N1CCOCC1 YDTUTAOENNWFDW-UHFFFAOYSA-N 0.000 claims 1
- OSAJIBRKWBPHOU-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-morpholin-4-yl-2-[(1-propan-2-ylimidazol-2-yl)amino]-3H-benzimidazole-5-carboxamide Chemical compound CC(C)n1ccnc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCOCC1 OSAJIBRKWBPHOU-UHFFFAOYSA-N 0.000 claims 1
- BZLLEZXUGYNHRT-UHFFFAOYSA-N N-(1H-indazol-6-yl)-6-morpholin-4-yl-2-[2-(trifluoromethyl)anilino]-3H-benzimidazole-5-carboxamide Chemical compound FC(F)(F)c1ccccc1Nc1nc2cc(C(=O)Nc3ccc4cn[nH]c4c3)c(cc2[nH]1)N1CCOCC1 BZLLEZXUGYNHRT-UHFFFAOYSA-N 0.000 claims 1
- LRMICGATKRUJIJ-UHFFFAOYSA-N N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=C(C=CC=C2F)F)C=C1N(CC)CC Chemical compound N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=C(C=CC=C2F)F)C=C1N(CC)CC LRMICGATKRUJIJ-UHFFFAOYSA-N 0.000 claims 1
- CHOBEYMOTFDZIM-UHFFFAOYSA-N N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=CC=C(C=C2)Cl)C=C1N(CC)CC Chemical compound N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=CC=C(C=C2)Cl)C=C1N(CC)CC CHOBEYMOTFDZIM-UHFFFAOYSA-N 0.000 claims 1
- FBIHASZKCOIBNS-UHFFFAOYSA-N N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=NC=CC=C2C(F)(F)F)C=C1N(CC)CC Chemical compound N1N=CC2=CC=C(C=C12)NC(=O)C1=CC2=C(NC(=N2)NC2=NC=CC=C2C(F)(F)F)C=C1N(CC)CC FBIHASZKCOIBNS-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- JLLUJHNJKJBMQU-UHFFFAOYSA-N n-(1h-indazol-5-yl)-6-(4-methylpiperazin-1-yl)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)C(=O)NC=2C=C3C=NNC3=CC=2)=CC2=C1N=C(NC=1C(=CC=CC=1)C(F)(F)F)N2 JLLUJHNJKJBMQU-UHFFFAOYSA-N 0.000 claims 1
- DYGPDMRKBQQVQY-UHFFFAOYSA-N n-(1h-indazol-5-yl)-6-morpholin-4-yl-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC2=CC(C(=O)NC=3C=C4C=NNC4=CC=3)=C(N3CCOCC3)C=C2N1 DYGPDMRKBQQVQY-UHFFFAOYSA-N 0.000 claims 1
- QMYIDZQUKBUCDL-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-(propylamino)-2-[2-(trifluoromethyl)anilino]-3h-benzimidazole-5-carboxamide Chemical compound N=1C=2C=C(C(=O)NC=3C=C4NN=CC4=CC=3)C(NCCC)=CC=2NC=1NC1=CC=CC=C1C(F)(F)F QMYIDZQUKBUCDL-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77249706P | 2006-02-10 | 2006-02-10 | |
| US60/772,497 | 2006-02-10 | ||
| US79118706P | 2006-04-11 | 2006-04-11 | |
| US60/791,187 | 2006-04-11 | ||
| PCT/US2007/003579 WO2007095124A2 (en) | 2006-02-10 | 2007-02-09 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009526072A JP2009526072A (ja) | 2009-07-16 |
| JP2009526072A5 true JP2009526072A5 (enExample) | 2011-07-07 |
| JP5188988B2 JP5188988B2 (ja) | 2013-04-24 |
Family
ID=38157823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008554398A Expired - Fee Related JP5188988B2 (ja) | 2006-02-10 | 2007-02-09 | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7820821B2 (enExample) |
| EP (2) | EP2295432A1 (enExample) |
| JP (1) | JP5188988B2 (enExample) |
| CN (2) | CN101379060B (enExample) |
| AU (1) | AU2007215247B2 (enExample) |
| BR (1) | BRPI0708034A2 (enExample) |
| CA (1) | CA2641744C (enExample) |
| IL (1) | IL192580A0 (enExample) |
| WO (1) | WO2007095124A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893267B2 (en) * | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| EP3205644A1 (en) | 2005-12-29 | 2017-08-16 | Celtaxsys Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| JP5480813B2 (ja) * | 2007-11-16 | 2014-04-23 | インサイト・コーポレイション | Ｊａｎｕｓキナーゼ阻害剤としての置換複素環 |
| WO2009084008A1 (en) * | 2007-12-28 | 2009-07-09 | Cadila Healthcare Limited | Process for preparing mycophenolate mofetil |
| CA2728228A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| JP5764064B2 (ja) | 2008-09-26 | 2015-08-12 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病薬として有用な新規な環状ベンゾイミダゾール誘導体 |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| MX2011004505A (es) | 2008-10-29 | 2011-05-31 | Merck Sharp & Dohme | Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos. |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| BRPI0923579A2 (pt) * | 2008-12-22 | 2020-01-14 | Millennium Pharm Inc | combinação de inibidores de aurora quinase e anticorpos anti-cd20 |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| MX2011013166A (es) | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Compuestos inhibidores de hdac de cicloalquilcarbamatobenzamida-an ilina. |
| EP2445345B1 (en) * | 2009-06-23 | 2014-08-27 | The Translational Genomics Research Institute | Benzamide derivatives |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| ES2679918T3 (es) * | 2010-02-18 | 2018-08-31 | Vtv Therapeutics Llc | Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8586604B2 (en) * | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| US8674113B2 (en) * | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2014008477A2 (en) | 2012-07-06 | 2014-01-09 | Duke University | Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch |
| KR102075885B1 (ko) | 2012-12-18 | 2020-02-11 | 버텍스 파마슈티칼스 인코포레이티드 | 세균 감염 치료용 만노스 유도체 |
| WO2014164658A1 (en) | 2013-03-12 | 2014-10-09 | Celtaxsys, Inc. | Methods of inhibiting leukotriene a4 hydrolase |
| HK1213268A1 (zh) | 2013-03-12 | 2016-06-30 | 沃泰克斯药物股份有限公司 | 用於治療細菌感染的甘露糖衍生物 |
| CA2906084A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP2968264A4 (en) | 2013-03-14 | 2016-11-02 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| WO2014193696A2 (en) | 2013-05-28 | 2014-12-04 | Transtech Pharma, Llc | Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| WO2015104662A1 (en) | 2014-01-10 | 2015-07-16 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| NZ722019A (en) | 2014-01-13 | 2022-07-01 | Aurigene Discovery Tech Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| MX2016017147A (es) * | 2014-06-20 | 2017-06-07 | Aurigene Discovery Tech Ltd | Compuestos de indazole substituidos como inhibidores de irak4. |
| WO2016028325A1 (en) | 2014-08-22 | 2016-02-25 | Duke University | Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
| JP7028765B2 (ja) * | 2015-05-22 | 2022-03-02 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | ベンズアミドおよび活性化合物組成物および使用方法 |
| EP3310767B1 (en) | 2015-06-22 | 2020-07-22 | Actelion Pharmaceuticals Ltd. | 2,5-disubstituted benzoxazole and benzothiazole compounds as nadph oxidase 4 inhibitors |
| EP3439656A4 (en) | 2016-04-07 | 2020-03-11 | Duke University | DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA |
| IL305150B2 (en) | 2017-03-31 | 2025-03-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
| SI3704108T1 (sl) | 2017-10-31 | 2024-07-31 | Curis, Inc. | Inhibitor irak4 v kombinaciji z inhibitorjem bcl-2 za uporabo pri zdravljenju raka |
| CA3093551A1 (en) * | 2018-03-29 | 2019-10-03 | Elex Biotech, Inc. | Compounds for treatment of cardiac arrhythmias and heart failure |
| ES3014615T3 (en) | 2018-05-31 | 2025-04-23 | Celltaxis Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| US20220177460A1 (en) | 2019-04-12 | 2022-06-09 | Mitobridge Inc. | Hmox1 inducers |
| US11427558B1 (en) | 2019-07-11 | 2022-08-30 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| JP7765088B2 (ja) * | 2019-12-02 | 2025-11-06 | ストーム・セラピューティクス・リミテッド | Ｍｅｔｔｌ３阻害剤としてのポリヘテロ環式化合物 |
| CN110903246A (zh) * | 2019-12-19 | 2020-03-24 | 赵洁 | 一种用于治疗甲状腺癌的化合物及其组合物和医药用途 |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CN112552287B (zh) * | 2020-12-16 | 2021-11-30 | 北京华氏精恒医药科技有限公司 | 一种吲哚类衍生物药物制剂及其制备方法 |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN115594671B (zh) * | 2021-07-08 | 2024-03-15 | 沈阳药科大学 | 苯并噻唑类衍生物及其制备方法和用途 |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5481271A (en) | 1977-12-09 | 1979-06-28 | Ouchi Shinkou Kagaku Kougiyou | Benzimidazole derivatives and manufacture |
| EP0178413A1 (en) * | 1984-08-17 | 1986-04-23 | Beecham Group Plc | Benzimidazoles |
| NZ221729A (en) | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| US6288100B1 (en) | 1995-06-06 | 2001-09-11 | American Home Products Corporation | Benzimidazole derivatives |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AU7001396A (en) | 1995-09-22 | 1997-04-09 | Takeda Chemical Industries Ltd. | Triazole compounds, their production and use |
| AU1618697A (en) * | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| US6114532A (en) * | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
| FR2778662B1 (fr) * | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2000143635A (ja) | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP4622020B2 (ja) * | 1999-02-26 | 2011-02-02 | 住友電気工業株式会社 | 絶縁被膜を有する酸化物超電導線材およびその製造方法 |
| ID30460A (id) * | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | Inhibitor-inhibitor protein siklik tirosin kinase |
| CA2378243C (en) * | 1999-08-04 | 2012-05-15 | Icagen, Inc. | Methods for treating or preventing pain and anxiety |
| ES2307528T3 (es) * | 1999-09-04 | 2008-12-01 | Astrazeneca Ab | Amidas como inhibidores para la piruvato deshidrogenasa. |
| US6316474B1 (en) * | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
| WO2001094318A2 (en) * | 2000-06-05 | 2001-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | Method for synthesis of substituted azole libraries |
| AU2002223492A1 (en) | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| EP1353674A1 (en) * | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
| WO2002053101A2 (en) * | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| PL365027A1 (en) | 2001-03-01 | 2004-12-27 | Shionogi & Co, Ltd. | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| US20030109714A1 (en) * | 2001-03-22 | 2003-06-12 | Neil Wishart | Transition metal mediated process |
| WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| US20030171411A1 (en) * | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
| JPWO2003068753A1 (ja) * | 2002-02-14 | 2005-06-02 | 小野薬品工業株式会社 | Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤 |
| JP2005529850A (ja) * | 2002-02-19 | 2005-10-06 | ファルマシア・イタリア・エス・ピー・エー | 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用 |
| DE10207037A1 (de) * | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| ATE447404T1 (de) * | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| WO2003082265A2 (en) | 2002-04-02 | 2003-10-09 | Fujisawa Pharmaceutical Co | Pharmaceutical composition for treating or preventing virus infectious diseases |
| DE10214832A1 (de) * | 2002-04-04 | 2003-10-16 | Merck Patent Gmbh | Phenylderivate 4 |
| US7135493B2 (en) * | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE602004024375D1 (de) * | 2003-02-14 | 2010-01-14 | Glaxo Group Ltd | Carboxamidderivate |
| AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| WO2004087153A2 (en) * | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| GB0311201D0 (en) * | 2003-05-15 | 2003-06-18 | Merck Sharp & Dohme | Therapeutic agents |
| EP1633740B1 (en) * | 2003-06-19 | 2011-11-09 | GlaxoSmithKline LLC | 5-(acylamino)indazole derivatives as kinase inhibitors |
| WO2005016914A1 (en) * | 2003-08-14 | 2005-02-24 | Smithkline Beecham Corporation | Chemical compounds |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| KR20060118472A (ko) * | 2003-10-16 | 2006-11-23 | 카이론 코포레이션 | 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용 |
| DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| WO2005090379A1 (en) | 2004-03-17 | 2005-09-29 | The Central Science Laboratory, 'csl' | Compounds and sensor for detecion of polycyclic aromatic hydrocarbons |
| US20060019967A1 (en) * | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| US20060068998A1 (en) * | 2004-09-27 | 2006-03-30 | Fuji Photo Film Co. Ltd. | Lubricant composition and triazine ring-containing compound |
| ATE414706T1 (de) | 2005-02-10 | 2008-12-15 | Smithkline Beecham Corp | Pyridopyrazolopyrimidinderivate und ihre anwendung gegen krebs und diabetes |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| WO2007064932A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc. | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
-
2007
- 2007-02-09 AU AU2007215247A patent/AU2007215247B2/en not_active Ceased
- 2007-02-09 EP EP10194622A patent/EP2295432A1/en not_active Withdrawn
- 2007-02-09 WO PCT/US2007/003579 patent/WO2007095124A2/en not_active Ceased
- 2007-02-09 CN CN2007800047858A patent/CN101379060B/zh not_active Expired - Fee Related
- 2007-02-09 US US11/704,431 patent/US7820821B2/en not_active Expired - Fee Related
- 2007-02-09 CA CA2641744A patent/CA2641744C/en not_active Expired - Fee Related
- 2007-02-09 EP EP07750418A patent/EP1987028A2/en not_active Withdrawn
- 2007-02-09 CN CN2012101215887A patent/CN102633783A/zh active Pending
- 2007-02-09 BR BRPI0708034-4A patent/BRPI0708034A2/pt not_active IP Right Cessation
- 2007-02-09 JP JP2008554398A patent/JP5188988B2/ja not_active Expired - Fee Related
-
2008
- 2008-07-02 IL IL192580A patent/IL192580A0/en unknown
-
2010
- 2010-02-10 US US12/703,604 patent/US8377983B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009526072A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| JP5970537B2 (ja) | キナーゼ阻害薬として活性な置換ピリミジニル−ピロール | |
| JP2014139226A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2012509263A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JPWO2021170109A5 (enExample) | ||
| RU2009101911A (ru) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы | |
| JP2009541268A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2015517981A5 (enExample) | ||
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2009525978A5 (enExample) | ||
| JP2012510989A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| JP2014527082A5 (enExample) |